Use of a liposomal formulation of amphotericin B for treating wound aspergillosis in a goliath heron (Ardea goliath)

Journal of Avian Medicine and Surgery

Volumn 18, Issue 3, 2004, Pages 162-166

  Bonar, Christopher J ^a   Lewandowski, Albert H ^a  

^a CLEVELAND METROPARKS ZOO   (United States)

Author keywords

Ardea goliath; Aspergillis fumigatus; Aspergillosis; Avian; Goliath heron; Liposomal amphotericin B; Skin wound

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; LIPOSOME; POVIDONE IODINE; WATER;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; BIRD; DEBRIDEMENT; DRUG FORMULATION; MALE; NEBULIZATION; NEPHROTOXICITY; NONHUMAN; PECTORAL MUSCLE; PHYSICAL EXAMINATION; RESPIRATORY SYSTEM; WOUND CARE;

ARDEA; ARDEA GOLIATH; ASPERGILLUS; AVES; MURINAE;

EID: 4844224271     PISSN: 10826742     EISSN: None     Source Type: Journal    
DOI: 10.1647/2003-003     Document Type: Article

References (14)

1. Redig PT. Aspergillosis in raptors. In: Cooper JE, Greenwood AG, eds. Recent Advances in the Study of Raptor Diseases. London, UK: Chiron Publications; 1981:117-122.
2. Campbell TW. Mycotic diseases. In: Harrison GJ, Harrison LR, eds. Clinical Avian Medicine and Surgery. Philadelphia, PA: WB Saunders; 1986:464-471.
3. Orosz SE. Overview of aspergillosis: pathogenesis and treatment options. Semin Avian Exotic Pet Med. 2000;9:59-65.
4. Joseph V. Aspergillosis in raptors. Semin Avian Exotic Pet Med. 2000;9:66-74.
5. Oglesbee B. Mycotic diseases. In: Altman RB, Clubb S, Dorrestein GM, Quesenberry K, eds. Avian Medicine and Surgery. Philadelphia, PA: WB Saunders; 1997:323-331.
6. Carpenter JW, Gentz EJ. Zoonotic diseases of avian origin. In: Altman RB, Clubb S, Dorrestein GM, Quesenberry K, eds. Avian Medicine and Surgery. Philadelphia, PA: WB Saunders; 1997:350-363.
7. Redig P. Fungal diseases. In: Samour J, ed. Avian Medicine. London, UK: Mosby; 2000:275-286.
8. Heidenreich M. Birds of Prey: Medicine and Management. Oxford, UK: Blackwell; 1997.
9. van Etten EW, van den Heuvel-de Groot C, Bakker-Woudenberg IA. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome), and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J Antimicrob Chemother. 1993;32:723-739.
10. Proffitt RT, Satorius A, Chiang S, et al. Pharmacology and toxicology of liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother. 1991;28(suppl B):49-61.
11. Flesness N. Physiologic Normal Values. Apple Valley, MN: International Species Inventory System; 2004.
12. Barsanti JA. Opportunistic fungal infections. In: Greene CE, ed. Clinical Microbiology and Infectious Diseases of the Dog and Cat. Philadelphia, PA: WB Saunders; 1984:728-732.
13. Bauck L. Mycoses. In: Ritchie B, Harrison G, Harrison LR, eds. Avian Medicine: Principles and Application. Lake Worth, FL: Wingers; 1994:998-1006.
14. Allen SD, Sorensen KN, Nejdl MJ, et al. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother. 1994;34:1001-1013.